TScan Therapeutics

TCRX

Market cap $59.8M

TCRX Hedge Fund Activity: Q1 2026 in Review

60 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q1 2026, worth a combined $32.8M — up 6.9% from $30.7M a quarter earlier.

Fund positioning in TCRX was balanced in Q1 2026: 11 funds opened new positions, 11 closed out, 15 added to existing stakes and 20 trimmed.

The largest buyer was Millennium Management, adding an estimated $1.13M. The largest seller was Aberdeen Group, cutting an estimated $927K.

• 60 institutional investors held TScan Therapeutics (TCRX) as of Q1 2026, down from 61 in Q4 2025.
• Funds reported $32.8M of TScan Therapeutics stock for Q1 2026, up 6.9% quarter-over-quarter.
• 11 funds opened new TScan Therapeutics positions in Q1 2026 and 11 closed out, a net change of 0 holders.
• The largest TScan Therapeutics buyer in Q1 2026 was Millennium Management, an estimated $1.13M added.
• The largest TScan Therapeutics seller in Q1 2026 was Aberdeen Group, an estimated $927K sold.

Based on aggregated 13F filings for Q1 2026.